On February 12, 2026, Rimag Group (2522) entered into a Loan Facility Agreement with Rimag Yuntai and Wuhan Ronggongshe, under which a credit facility of up to RMB44 million may be provided. According to the announcement, the interest rate under this facility will not exceed 6%, with the precise rate to be confirmed in subsequent drawdown documents.

The drawdown period extends until December 29, 2028, and each single loan term may be up to 36 months. Failure to make timely repayment triggers penalty interest at four times the one-year loan prime rate. The stated purpose of the facility is to offer financial support for business operations and expansion in the relevant subsidiaries’ medical solutions services.

Rimag Yuntai and Wuhan Ronggongshe are each majority-owned by Rimag Group and partially owned by Shanghai Ronggongshe. Due to overlapping beneficial ownership by the Group’s chairman, the transaction constitutes a connected transaction under the Listing Rules. When aggregated with a previous RMB50 million facility guaranteed by Rimag Group and Shanghai Ronggongshe, the highest applicable percentage ratio is above 0.1% but below 5%. As a result, the loan facility is subject to reporting and announcement requirements but exempt from circular and independent shareholders’ approval under Chapter 14A of the Listing Rules.